Challenges and strategies: Scalable and efficient production of mesenchymal stem cells-derived exosomes for cell-free therapy
- PMID: 36828131
- DOI: 10.1016/j.lfs.2023.121524
Challenges and strategies: Scalable and efficient production of mesenchymal stem cells-derived exosomes for cell-free therapy
Abstract
Exosomes are small membrane vesicles secreted by most cell types, and widely exist in cell supernatants and various body fluids. They can transmit numerous bioactive elements, such as proteins, nucleic acids, and lipids, to affect the gene expression and function of recipient cells. Mesenchymal stem cells (MSCs) have been confirmed to be a potentially promising therapy for tissue repair and regeneration. Accumulating studies demonstrated that the predominant regenerative paradigm of MSCs transplantation was the paracrine effect but not the differentiation effect. Exosomes secreted by MSCs also showed similar therapeutic effects as their parent cells and were considered to be used for cell-free regenerative medicine. However, the inefficient and limited production has hampered their development for clinical translation. In this review, we summarize potential methods to efficiently promote the yield of exosomes. We mainly focus on engineering the process of exosome biogenesis and secretion, altering the cell culture conditions, cell expansion through 3D dynamic culture and the isolation of exosomes. In addition, we also discuss the application of MSCs-derived exosomes as therapeutics in disease treatment.
Keywords: Cell-free therapy; Clinical translation; Exosomes; Mesenchymal stem cells; Scalable approach; Tissue repair and regeneration.
Copyright © 2023 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that there are no conflicts of interest.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
